Breast Cancer (Therapy)

Trial Using Mesenchymal Stem Cell Transplants Initiated

Published in Women's Health Weekly, October 12th, 1998

Osiris Therapeutics, Inc., Baltimore, Maryland, announced the initiation of a Phase I/II human clinical trial of Stromagen in metastatic breast cancer patients receiving high dose chemotherapy and hematopoietic stem cell transplantation.

Stromagen, an infused, autologous, ex vivo, expanded human mesenchymal stem cell (hMSC) product, has been shown in preclinical studies to enhance hematopoietic stem cell engraftment and differentiation.

Mesenchymal stem cells give rise to marrow stromal cells, which produce the spongy matrix that constitutes the bone marrow microenvironment. These marrow stromal cells contribute directly to blood cell formation by...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (1998-10-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry